| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
We identified mutations in small GTPases in the genomes of triple negative breast cancers (TNBCs). These proteins were found to be oncogenic in a nude mice tumorigenic assay.
The clonal analysis suggested that TP53 mutations and silencing of BRCA1 were earlier events during TNBC carcinogenesis, while mutations in small GTPases were considered to develop at later stage of tumor progression. Taken together, while, given its potent oncogenic capacity, mutations in GTPases is a potential therapeutic target, resistance may be acquired as a result of expansion of tumor clones without such mutations.
|
